Cargando…

Variant Aldehyde Dehydrogenase 2 (ALDH2*2) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial Infarction

BACKGROUND: Mitochondrial aldehyde dehydrogenase 2 (ALDH2) plays a key role in removing toxic aldehydes. Deficient variant ALDH2*2 genotype is prevalent in up to 40% of the East Asians and reported to be associated with acute myocardial infarction (AMI). To elucidate the mechanisms underlying the as...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Yuji, Hokimoto, Seiji, Harada, Eisaku, Kinoshita, Kenji, Nakagawa, Kazuko, Yoshimura, Michihiro, Ogawa, Hisao, Yasue, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889196/
https://www.ncbi.nlm.nih.gov/pubmed/27153870
http://dx.doi.org/10.1161/JAHA.116.003247
_version_ 1782434964263927808
author Mizuno, Yuji
Hokimoto, Seiji
Harada, Eisaku
Kinoshita, Kenji
Nakagawa, Kazuko
Yoshimura, Michihiro
Ogawa, Hisao
Yasue, Hirofumi
author_facet Mizuno, Yuji
Hokimoto, Seiji
Harada, Eisaku
Kinoshita, Kenji
Nakagawa, Kazuko
Yoshimura, Michihiro
Ogawa, Hisao
Yasue, Hirofumi
author_sort Mizuno, Yuji
collection PubMed
description BACKGROUND: Mitochondrial aldehyde dehydrogenase 2 (ALDH2) plays a key role in removing toxic aldehydes. Deficient variant ALDH2*2 genotype is prevalent in up to 40% of the East Asians and reported to be associated with acute myocardial infarction (AMI). To elucidate the mechanisms underlying the association of ALDH2*2 with AMI, we compared the clinical features of AMI patients with ALDH2*2 to those with wild‐type ALDH2*1/*1. METHODS AND RESULTS: The study subjects consisted of 202 Japanese patients with acute ST‐segment elevation myocardial infarction (STEMI) (156 men and 46 women; mean age, 67.3±12.0) who underwent primary percutaneous coronary intervention (PCI). In 85 patients, provocation test for coronary spasm was also done 6 month post‐PCI. ALDH2 genotyping was performed by direct application of the TaqMan polymerase chain system. Of the 202 patients, 103 (51.0%) were carriers of ALDH2*2 and 99 (49.0%) those of ALDH2*1/*1. There were no differences in clinical features between ALDH2*2 and ALDH2*1/*1 carrier groups except higher frequencies of coronary spasm and alcohol flush syndrome (AFS) (88.6% vs 56.1%; P=0.001 and 94.3% vs 17.6%; P<0.001), less‐frequent alcohol habit (14.6% vs 51.5%; P<0.001), and higher peak plasma creatine phophokinase levels (2224 vs 1617 mg/dL; P=0.002) in the ALDH2*2 than the ALDH2*1/*1 carrier group. CONCLUSIONS: ALDH2*2 is prevalent (51.0%) among Japanese STEMI patients, and those with ALDH2*2 had higher frequencies of coronary spasm and AFS and more‐severe myocardial injury compared to those with ALDH2*1/*1.
format Online
Article
Text
id pubmed-4889196
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48891962016-06-09 Variant Aldehyde Dehydrogenase 2 (ALDH2*2) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial Infarction Mizuno, Yuji Hokimoto, Seiji Harada, Eisaku Kinoshita, Kenji Nakagawa, Kazuko Yoshimura, Michihiro Ogawa, Hisao Yasue, Hirofumi J Am Heart Assoc Original Research BACKGROUND: Mitochondrial aldehyde dehydrogenase 2 (ALDH2) plays a key role in removing toxic aldehydes. Deficient variant ALDH2*2 genotype is prevalent in up to 40% of the East Asians and reported to be associated with acute myocardial infarction (AMI). To elucidate the mechanisms underlying the association of ALDH2*2 with AMI, we compared the clinical features of AMI patients with ALDH2*2 to those with wild‐type ALDH2*1/*1. METHODS AND RESULTS: The study subjects consisted of 202 Japanese patients with acute ST‐segment elevation myocardial infarction (STEMI) (156 men and 46 women; mean age, 67.3±12.0) who underwent primary percutaneous coronary intervention (PCI). In 85 patients, provocation test for coronary spasm was also done 6 month post‐PCI. ALDH2 genotyping was performed by direct application of the TaqMan polymerase chain system. Of the 202 patients, 103 (51.0%) were carriers of ALDH2*2 and 99 (49.0%) those of ALDH2*1/*1. There were no differences in clinical features between ALDH2*2 and ALDH2*1/*1 carrier groups except higher frequencies of coronary spasm and alcohol flush syndrome (AFS) (88.6% vs 56.1%; P=0.001 and 94.3% vs 17.6%; P<0.001), less‐frequent alcohol habit (14.6% vs 51.5%; P<0.001), and higher peak plasma creatine phophokinase levels (2224 vs 1617 mg/dL; P=0.002) in the ALDH2*2 than the ALDH2*1/*1 carrier group. CONCLUSIONS: ALDH2*2 is prevalent (51.0%) among Japanese STEMI patients, and those with ALDH2*2 had higher frequencies of coronary spasm and AFS and more‐severe myocardial injury compared to those with ALDH2*1/*1. John Wiley and Sons Inc. 2016-05-06 /pmc/articles/PMC4889196/ /pubmed/27153870 http://dx.doi.org/10.1161/JAHA.116.003247 Text en © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Mizuno, Yuji
Hokimoto, Seiji
Harada, Eisaku
Kinoshita, Kenji
Nakagawa, Kazuko
Yoshimura, Michihiro
Ogawa, Hisao
Yasue, Hirofumi
Variant Aldehyde Dehydrogenase 2 (ALDH2*2) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial Infarction
title Variant Aldehyde Dehydrogenase 2 (ALDH2*2) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial Infarction
title_full Variant Aldehyde Dehydrogenase 2 (ALDH2*2) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial Infarction
title_fullStr Variant Aldehyde Dehydrogenase 2 (ALDH2*2) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial Infarction
title_full_unstemmed Variant Aldehyde Dehydrogenase 2 (ALDH2*2) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial Infarction
title_short Variant Aldehyde Dehydrogenase 2 (ALDH2*2) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial Infarction
title_sort variant aldehyde dehydrogenase 2 (aldh2*2) is a risk factor for coronary spasm and st‐segment elevation myocardial infarction
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889196/
https://www.ncbi.nlm.nih.gov/pubmed/27153870
http://dx.doi.org/10.1161/JAHA.116.003247
work_keys_str_mv AT mizunoyuji variantaldehydedehydrogenase2aldh22isariskfactorforcoronaryspasmandstsegmentelevationmyocardialinfarction
AT hokimotoseiji variantaldehydedehydrogenase2aldh22isariskfactorforcoronaryspasmandstsegmentelevationmyocardialinfarction
AT haradaeisaku variantaldehydedehydrogenase2aldh22isariskfactorforcoronaryspasmandstsegmentelevationmyocardialinfarction
AT kinoshitakenji variantaldehydedehydrogenase2aldh22isariskfactorforcoronaryspasmandstsegmentelevationmyocardialinfarction
AT nakagawakazuko variantaldehydedehydrogenase2aldh22isariskfactorforcoronaryspasmandstsegmentelevationmyocardialinfarction
AT yoshimuramichihiro variantaldehydedehydrogenase2aldh22isariskfactorforcoronaryspasmandstsegmentelevationmyocardialinfarction
AT ogawahisao variantaldehydedehydrogenase2aldh22isariskfactorforcoronaryspasmandstsegmentelevationmyocardialinfarction
AT yasuehirofumi variantaldehydedehydrogenase2aldh22isariskfactorforcoronaryspasmandstsegmentelevationmyocardialinfarction